Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?

计划入组 32 人 · 首次发布于 2021 年 3 月 24 日

Bio-ADM as a Biomarker of Refilling in Chronic Hemodialysis Patient

计划入组 150 人 · 首次发布于 2022 年 4 月 21 日

Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB

计划入组 301 人 · 首次发布于 2017 年 3 月 21 日

Pegylated Human Adrenomedullin

Pegylated adrenomedullin

human AM/AMBP-1 (TheraSource)

BIOACTIVE NUTRITIONAL, INC.

United States

52 North Health Ltd.

United Kingdom

NHI-1

United States

SphingoTec to Present New penKid Sepsis Data and Co-Host Sepsis Symposium at ESICM Lives 2026

Enibarcimab Shows Promising Results in Biomarker-Guided Septic Shock Treatment

Hyundai ADM Bio Pivots Strategy to Focus on Immunotherapy Combinations for Cancer Treatment